Cancer Vaccines
Introgen Comments on SEC Action Against Short Seller of Its Stock
Published in Law and Health Weekly, March 17th, 2007
Yesterday, the U.S. Securities and Exchange Commission (SEC) announced a litigation settlement with a short seller, and its manager, of Introgen Therapeutics, Inc.'s (NASDAQ:INGN) securities. According to the SEC complaint, the settling Defendant, the hedge fund Crestview Capital Partners LLC, defrauded Introgen by falsely representing to Introgen that Crestview did not short sell Introgen securities prior to a registered direct placement of Introgen stock, when in fact it did engage in such short selling; and based on the hedge fund's misrepresentation, Introgen allowed the hedge fund to participate in the stock placement. Introgen is reviewing remedies that may be available to it and its...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- Biomedical Engineering
New biomedical engineering study findings recently were reported by researchers at Center for Biomedical Ethics and Law - Bone Research
Studies from University of North Carolina, Department of Orthopaedic Surgery describe new findings in bone research - Chronic Disease Therapy
Scientists at National University of Singapore, Department of Anaesthesia detail research in chronic disease therapy - Clinical Trial Research
Bentley Pharmaceuticals Announces Fourth Quarter and Full Year 2006 Financial Results - Clinical Trials Research
Cytori Therapeutics to Raise $21.5 Million in Registered Direct Offering - Cord Blood
Cord Blood Registry Advances Leadership Position in Growing Family Cord Blood Banking Industry - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
